Optimizing adherence to adjuvant imatinib in gastrointestinal stromal tumor.

ABSTRACT: The increasing use of patient-administered oral anticancer drugs is paralleled by new challenges in maintaining treatment adherence. These challenges are particularly significant with adjuvant therapies for prevention of disease recurrence, where the benefits of ongoing treatment are not readily apparent to patients. Nurse practitioners and physician assistants (collectively referred to as advanced practitioners) play integral roles in providing education on disease and treatment to patients that can increase adherence to oral therapies and ideally improve outcomes. For patients with gastrointestinal stromal tumor (GIST), the oral targeted therapy imatinib has become the mainstay of treatment for advanced and recurrent disease and as adjuvant therapy following surgical resection. Recent da

SUBMITTER: Tetzlaff ED 

PROVIDER: S-EPMC4093429 | biostudies-literature | 2013 Jul

REPOSITORIES: biostudies-literature